• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Q Biomed Technology Partner Mannin Research Inc. To Participate In A Webcast On Innovating For Ophthalmic Diseases

    Matthew Spizziri
    Oct. 19, 2016 01:37PM PST
    Biotech Investing
    Biotech Investing

    NEW YORK, October 19, 2016 — Q BioMed Inc. (OTCQB:QBIO), technology partner Mannin Research Inc. will present in a webcast on Innovating for Ophthalmic Diseases on October 20th at 10AM ET.

    NEW YORK, October 19, 2016 — Q BioMed Inc. (OTCQB:QBIO), technology partner Mannin Research Inc. will present in a webcast on Innovating for Ophthalmic Diseases on October 20th at 10AM ET.
    Dr. George Nikopoulos, CEO and President of Mannin Research Inc. will participate in a BioPharma Dealmakers webcast, sponsored in part by Mannin Research Inc., featuring three companies innovating in therapies for eye disorders.
    Please register here to participate > Webcast registration link
    This webcast will explore some of the latest advances in the ophthalmic field through discussion with representatives from companies developing a range of innovative therapies for eye disorders, including the use of iPS cells, eye drops to deliver small-molecule drugs and complement inhibition.
    The webcast will conclude with a live roundtable discussion and a Q&A section to allow you to participate and put your own questions to the speakers.
    Dr. Nikopoulos has worked with and advised a number of biotechnology, pharmaceutical and med-tech companies. Dr. Nikopoulos’ expertise includes translating complex technologies and innovations into strategies for commercialization, market research, and business development as well as pre-clinical toxicology study design.
    Other webcast participants include:

    • Hardy TS Kagimoto, MD, President, Representative Director and CEO of HEALIOS K.K.
    • Dr. George Nikopoulos, CEO & President of Mannin Research Inc.
    • Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.

    Connect with Q BioMed Inc. (OTCQB:QBIO) to receive an Investor Presentation.

    small molecule drugsbusiness development
    The Conversation (0)

    Go Deeper

    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×